二、承诺函的主要内容 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏并对其内容的 真实性、准确性和完整性承担个别及连带责任。 广西五洲交通股份有限公司（以下简称"公司"）近日收到公司控股股东广西交通投资集团有限公司（以 下简称"交投集团"）通知，交投集团已获得中信银行股份有限公司南宁分行（以下简称"中信银行"）出 具的贷款承诺函，中信银行承诺对交投集团股份增持事项提供贷款支持，贷款资金最高不超过人民币 1.53亿元，具体情况如下： 一、增持计划的主要内容 交投集团基于对公司长期价值的认可和未来发展的信心，计划自2025年9月15日起12个月内，通过上海 证券交易所集中竞价交易等合法合规方式增持公司股份，拟增持金额不低于人民币0.85亿元（含）且不 高于人民币1.7亿元（含）。具体内容详见公司于2025年9月16日在上海证券交易所网站 （www.sse.com.cn）披露的《五洲交通关于控股股东增持股份计划的公告》（公告编号：临 2025- 034）。 中信银行承诺在符合贷款条件的前提下，同意对交投集团股份增持事项提供贷款支持。贷 ...

Core Viewpoint - The controlling shareholder of Anhui Construction Group Co., Ltd. has successfully completed a share buyback plan, demonstrating confidence in the company's future development and long-term investment value [2][3][6]. Summary by Sections Share Buyback Plan - The controlling shareholder, Anhui Construction Group Holdings Co., Ltd., announced a plan to increase its stake in the company by acquiring between 1% and 2% of the total shares, with a maximum investment of RMB 200 million [2]. - The buyback plan was executed from May 29 to September 12, 2025, resulting in the acquisition of 34,330,010 A-shares, which is approximately 2.00% of the total share capital, amounting to RMB 163,076,974.28 (excluding taxes) [2][3]. Shareholding Changes - As of September 12, 2025, the controlling shareholder held a total of 585,968,794 shares, representing 34.14% of the company's total share capital [6]. - The buyback activity was conducted in compliance with relevant laws and regulations, and it did not affect the company's listing status or change the controlling shareholder [6]. Legal Compliance and Disclosure - The company has fulfilled its information disclosure obligations in accordance with the Shanghai Stock Exchange's rules and regulations [6]. - A legal opinion was provided by Anhui Tianhe Law Firm regarding the buyback, confirming its compliance with applicable laws [6].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002252 证券简称：上海莱士 公告编号：2025-063 上海莱士血液制品股份有限公司 关于控股股东增持公司股份计划实施完成的公告 公司控股股东海盈康（青岛）医疗科技有限公司保证向本公司提供的信息内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、增持计划的主要内容：上海莱士血液制品股份有限公司（"上海莱士"、"公司"）于2025年5月22日披 露了《关于控股股东增持股份计划的公告》（公告编号：2025-043），基于对上海莱士未来发展的信心 和长期投资价值的认同，增强投资者信心，控股股东海盈康（青岛）医疗科技有限公司（"海盈康"）计 划自本次增持计划公告披露之日起6个月内（除法律、法规及深圳证券交易所业务规则等有关规定不准 增持公司股票的期间之外），通过集中竞价方式增持公司股份，拟增持金额不低于人民币25,000万元， 且不超过人民币50,000万元（均含本数且不包含交易费用）（以下简称"本次增持计划"）。本次增持计 划不设置增持价格区间，增持主体基于 ...

Core Viewpoint - The controlling shareholder of Shanghai Pharmaceuticals, Shanghai Shiyuan Group, plans to increase its stake in the company through its wholly-owned subsidiary, Shanghai Shiyuan International Investment Co., Ltd. [2][3] Group 1: Basic Information of the Increasing Entity - The increasing entity, Shanghai Shiyuan International Investment Co., Ltd., is a wholly-owned subsidiary of Shanghai Shiyuan Group, which is the controlling shareholder of Shanghai Pharmaceuticals [2]. - After the recent purchase of 100,000 H-shares on September 15, 2025, Shanghai Shiyuan International now holds 300,538,000 H-shares, accounting for 8.104% of the total share capital of the company [2]. Group 2: Main Content of the Increasing Plan - The controlling shareholder, Shanghai Shiyuan Group, plans to increase its stake through Shanghai Shiyuan International by acquiring between 55 million to 74 million H-shares over the next 12 months, not exceeding 2% of the company's voting shares [3]. - The increase will be executed through the Hong Kong Stock Exchange's centralized bidding system, with no fixed price range set for the purchases, allowing for flexibility based on market conditions [3]. Group 3: Other Relevant Information - The increasing plan complies with the relevant laws and regulations, including the Securities Law of the People's Republic of China and the Hong Kong Securities and Futures Commission's rules [7]. - The controlling shareholder and its subsidiaries commit not to reduce their holdings of the company's shares during the implementation of the increasing plan and for six months thereafter [7].

Core Viewpoint - The company, Meizhong Jiahua (02453), announced that its controlling shareholder, Concord Medical Services Holdings Limited (CCM), plans to increase its stake in the company within the next 12 months [1] Group 1: Shareholder Actions - CCM intends to acquire shares through its subsidiaries using its own funds in the open market [1] - The specific details of the share acquisition will be disclosed in accordance with regulations [1] Group 2: Strategic Intent - The share buyback plan aims to solidify CCM's controlling position and increase its ownership percentage [1] - This move is intended to convey a positive message to the market regarding CCM's confidence in the company's future prospects and long-term development [1]

Core Viewpoint - Concord Medical Services Holdings Limited (CCM) plans to increase its stake in the company within 12 months, signaling confidence in the company's future prospects [1] Group 1 - CCM will conduct the share buyback through its subsidiaries using its own funds in the open market [1] - The buyback aims to consolidate CCM's controlling position and increase its shareholding percentage [1] - The company will disclose specific buyback transactions in accordance with regulations [1]

增持计划旨在巩固CCM的控股地位，提高CCM的持股比例，并向市场传递控股股东对集团未来前景及 长远发展充满信心的积极信息。 格隆汇9月12日丨美中嘉和(02453.HK)发布公告，公司获公司控股股东Concord Medical Services Holdings Limited("CCM")告知，CCM计划于本公告起计12个月内增持公司股权。公司已获告知，为进行增持， CCM将透过其附属公司以自有资金于公开市场进行增持，具体增持交易将根据规则及时披露。 ...

2025年9月10日湖北宜化公告，截至披露日公司总股本为1,088,522,212股。2025年6月10日至9月9日，控 股股东宜化集团通过深交所集中竞价增持公司12,499,000股，占当前总股本1.15%。本次增持后，宜化 集团持股增至239,826,044股，占比22.03%，权益变动触及1%整数倍。此次增持是为提振投资者信心、 维护股价稳定，不会导致股权分布不合上市条件及控制权变化。此前宜化集团披露增持计划未实施完 毕，将继续执行。 ...

Core Viewpoint - The controlling shareholder of Huaxi Biotechnology Co., Ltd. plans to increase its stake in the company, reflecting confidence in the company's future development and long-term investment value [2]. Summary by Sections Shareholder Buyback Plan - Huaxi Xinyu Investment Co., Ltd., the controlling shareholder, intends to increase its stake in Huaxi Biotechnology starting from August 8, 2025, for a period of six months, with a planned investment of no less than RMB 200 million and no more than RMB 300 million [2]. - The buyback will not exceed 1% of the company's total share capital, and the purchase price will not exceed RMB 70 per share [2]. Implementation Status - As of September 5, 2025, Huaxi Xinyu has acquired 3,496,931 shares, representing 0.73% of the total share capital, with a total expenditure of approximately RMB 200.68 million, surpassing the lower limit of the planned investment [2]. Risks Related to the Buyback Plan - There are potential risks that the buyback plan may not be implemented as expected due to changes in the capital market or other unpredictable factors [3][4].

Core Viewpoint - Guizhou Moutai has received a loan commitment from Agricultural Bank of China to support its controlling shareholder's stock buyback plan, with a loan amount not exceeding RMB 2.7 billion [2][4]. Group 1: Loan Commitment and Terms - The loan from Agricultural Bank of China is intended to support the stock buyback by Guizhou Moutai's controlling shareholder, Moutai Group, with a maximum amount of RMB 2.7 billion [2]. - The loan has a term of three years and is specifically designated for the purpose of increasing the company's stock holdings [2][4]. - The implementation of the loan is subject to the fulfillment of conditions recognized by Agricultural Bank and regulatory requirements [4]. Group 2: Stock Buyback Plan - Moutai Group plans to increase its shareholding in Guizhou Moutai between September 1, 2025, and February 28, 2026, with a total investment of no less than RMB 3 billion and no more than RMB 3.3 billion [4]. - The funding for the buyback will come from both self-owned and self-raised funds [4]. - There is no set price range for the buyback, allowing Moutai Group to act based on market conditions and the company's stock price [5]. Group 3: Recent Buyback Activity - On September 1, Moutai Group executed a buyback of 67,800 shares, representing 0.0054% of the total share capital, with an investment of approximately RMB 100 million [5]. - Moutai Group has committed not to reduce its shareholdings during the buyback period and the statutory timeframe [5].